Stocks & Investing
Stocks and Investing
Stocks and Investing
Wed, March 16, 2022
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Vamil Divan Maintained (XERS) at Strong Buy with Decreased Target to $6 on, Mar 16th, 2022
Vamil Divan of Mizuho, Maintained "Xeris Biopharma Holdings, Inc." (XERS) at Strong Buy with Decreased Target from $8 to $6 on, Mar 16th, 2022.
Vamil has made no other calls on XERS in the last 4 months.
There are 2 other peers that have a rating on XERS. Out of the 2 peers that are also analyzing XERS, 0 agree with Vamil's Rating of Hold.
These are the ratings of the 2 analyists that currently disagree with Vamil
- Roanna Ruiz of "SVB Leerink" Maintained at Buy with Decreased Target to $6 on, Wednesday, February 16th, 2022
- Oren Livnat of "HC Wainwright & Co." Maintained at Strong Buy with Increased Target to $5.4 on, Friday, December 31st, 2021
